ImmuPharma (AIM:IMM) has filed an international Patent Cooperation Treaty (PCT) application covering its P140 precision medicine approach in autoimmune disease.
The filing includes intellectual property around Type M, a biologically defined patient population identified as having an increased likelihood or magnitude of response to P140.
The PCT application builds on the original UK priority patent filed in August 2025 and disclosed by the company the following month.
During the 12-month priority period, ImmuPharma generated additional experimental data supporting the scientific basis of the P140 and Type M approach, which has now been folded into the international filing.
The application will proceed through the PCT's international phase, including a patent search and subsequent publication, before ImmuPharma decides which national and regional jurisdictions to pursue for protection.
Dr Sébastien Goudreau, ImmuPharma's Chief Scientific Officer, said the filing "enables us to progress our international patent strategy alongside the broader development of P140."
The company continues to describe P140 as a core value driver and said it remains focused on completing a commercial deal for the asset during 2026.
Chief Executive Tim McCarthy said the PCT filing, together with the newly incorporated data, keeps P140 progressing "as a key strategic asset for ImmuPharma."
News Intelligence what this means for the company
ImmuPharma has filed a PCT patent application covering P140 and its Type M patient biomarker, building on a UK priority patent filed in August 2025 with additional experimental data generated during the priority period. The company reaffirms P140 as a core value driver and maintains its target to complete a commercial deal for the asset by end-2026.
The PCT filing extends IP protection for P140's precision medicine approach internationally, but remains a procedural step in patent prosecution rather than a clinical or commercial milestone. The outcome depends on ImmuPharma's ability to execute the stated 2026 licensing target and on whether Type M biomarker data proves material to a partner's commercial interest.
Insights assembled by AI. Editor-reviewed and grounded in tickstock’s coverage and proprietary knowledge graph.
Content is for informational purposes only, not financial advice.
